A respiratory gas exchange catheter: In vitro and in vivo tests in large animals  by Hattler, Brack G. et al.
A respiratory gas exchange catheter: In vitro and in vivo
tests in large animals
Brack G. Hattler, MD, PhD
Laura W. Lund, PhD
Joseph Golob, BS
Heide Russian, BS
Michael F. Lann, BS
Thomas L. Merrill, PhD
Brian Frankowski, AD
William J. Federspiel, PhD
Objectives: Acute respiratory failure is associated with a mortality of 40% to 50%,
despite advanced ventilator support and extracorporeal membrane oxygenation. A
respiratory gas exchange catheter (the Hattler Catheter) has been developed as an
oxygenator and carbon dioxide removal device for placement in the vena cava and
right atrium in the treatment of acute respiratory failure to improve survival.
Methods: Differing from a previously clinically tested intravenous gas exchange
device (ie, IVOX), the Hattler Catheter incorporates a small, pulsating balloon
surrounded by hollow fibers. The pulsating balloon redirects blood toward the fibers,
enhances red cell contact with the membrane, and significantly improves gas
exchange so that smaller catheter devices are still efficient on insertion and can be
inserted through the jugular or femoral vein. Devices were tested in mock circula-
tory loops and in short-term (8 hours) and long-term (4 days) experiments in calves
to study the effect of various sized balloons and the anatomic location of the device
in the venous system as a function of hemodynamics and gas exchange.
Results: In vitro performance in water demonstrates an oxygen delivery (VO2) of
140 8.9 mL  min1  m2 and a carbon dioxide removal (VCO2) of 240 6.1 mL
 min1  m2. Acute in vivo experiments demonstrate a maximum carbon dioxide
consumption of 378  11.2 mL  min1  m2. Devices positioned in the right
atrium had an average carbon dioxide exchange of 305 mL  min1  m2, whereas
in the inferior vena cava position carbon dioxide exchange was 255 mL  min1 
m2. Devices have been tested long term in calves, with gas exchange rates
maintained over this time interval (carbon dioxide consumption, 265  35 mL 
min1  m2). Plasma-free hemoglobin levels at the end of 4 days have been 4.8 
3.2 mg/dL. Hemodynamic measurements, including a decrease in cardiac outputs
and increased mean pressure decreases across the device become significant only
with the larger balloon (40-mL) devices (P  .05, 40-mL vs 13-mL devices).
Autopsies show no end-organ damage. The device linearly increases its carbon
dioxide output with progressive hypercapnea, predicting its ability to meet tidal
volume reduction in the therapy of respiratory failure.
Conclusions: Progress has been made toward developing an intravenous gas ex-
change catheter to provide temporary pulmonary support for patients in acute
respiratory failure.
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Acute respiratory failure from a variety ofcauses is one of the main concerns in thecare of patients in intensive care units.One form of severe acute respiratory fail-ure, the acute respiratory distress syn-drome (ARDS), although first described
by Ashbaugh and colleagues1 in 1967, continues to exhibit
a mortality in adults of approximately 40% to 50%, despite
a better understanding of the pathophysiology responsible
for this condition.2,3 For the patient with acute respiratory
failure, maintaining gas exchange at a level consistent with
survival is associated frequently with progressively increas-
ing levels of ventilator support. A review of our recent
experience with 1839 patients who were placed on ventila-
tors because of a primary respiratory problem has indicated,
not surprisingly, that mortality after intubation, oxygen de-
livery, and use of the respirator increases the longer a
patient is ventilated.4 For the 799 patients within this group
requiring ventilation for greater than 96 hours, a mortality of
37% was noted. These findings underscore the need for
improved approaches to this patient population and consti-
tute the basis for the continuing interest in the development
of better ventilator strategies, new drug therapies, and arti-
ficial lung devices for the treatment of acute lung failure and
the management of patients on ventilators.5-11
We have concentrated our efforts in one of these areas as
it relates to the development of an intravenous hollow fiber
membrane respiratory assist catheter, the Hattler Catheter
(HC).11-21* Differing from a previous intravenous gas ex-
change device tested clinically (the IVOX), it incorporates a
balloon surrounded by microporous hollow fiber mem-
branes.22-24 The pulsating balloon redirects blood toward the
fibers, enhances red cell contact with the membranes, and
significantly improves oxygen and carbon dioxide ex-
change.4,12,25 The underlying bioengineering concepts that
are fundamental to gas exchange in blood have been instru-
mental in guiding research in this new field and have formed
the basis for our continuing and most recent efforts in this
area. Our clinical goal has been to provide 50% of basal
oxygen and carbon dioxide exchange, as determined by
calculated gas exchange requirements for an adult patient
with various levels of pulmonary damage and residual func-
tional lung (Figure 1). The ability to achieve a life-sustain-
ing arterial oxygen saturation of greater than 90% (PO2 of 60
mm Hg) with only 30% of the lung still functional would
require that a respiratory assist catheter add an additional
100 to 125 mL/min oxygen to the patient’s bloodstream
(Figure 1). This represents approximately 50% of basal
oxygen requirements.
This article describes the results of complementary in
vitro and bovine in vivo experiments conducted to compare
the gas exchange performance and hemodynamic effects of
devices having different balloon sizes but the same fiber
length and surface area. The in vitro tests were performed to
characterize and compare the gas exchange performance of
devices with design-parameter variations, such as balloon
size, under carefully controlled conditions. The acute in
vivo tests were then performed to evaluate whether these
performance characteristics were sensitive to anatomic and
physiologic variations in situ and to evaluate their hemody-
namic effects. Finally, chronic 4-day in vivo trials were
conducted with the device determined most optimal on the
basis of the in vitro and acute in vivo studies to evaluate
device performance and hemodynamic effects over time.
Materials and Methods
Respiratory Assist Catheters
The HC devices used in these experiments were sized on the basis
of the diameters and lengths of the inferior vena cava (IVC) and
superior vena cava (SVC) of a calf, which have more constrained
dimensions than those of an adult human. Each device had a fiber
bundle surface area of 0.17 m2 comprised of 600 polypropylene
hollow fiber membranes (x30-240; Celgard, Charlotte, NC) with
inner and outer diameters of 240 m and 300 m, respectively.
The proximal and distal manifolds in which the hollow fibers were
potted had a diameter of 9 mm, which dictates the minimal
insertional size of the device. A schematic of the catheter is shown
in Figure 2. Hollow fiber membrane mats surround the central
balloon in concentric layers. The 3 ports to the exit manifold
supply oxygen, a vacuum, and a helium port connected to an
external console that inflates and deflates the balloon at up to 300
beats/min. Devices having 3 balloon sizes were tested: a 13-mL
balloon with a diameter of 9.5 mm, a 25-mL balloon with a
diameter of 12.5 mm, and a 40-mL balloon with a diameter of 15
mm.
In Vitro Characterization
Before in vivo testing, each device was characterized in a mock
venous circulatory test circuit with water at 37°C. Water is used
routinely in testing gas exchange parameters of artificial lung
devices because it is easier to handle on a daily basis than is blood.
Water data, however, are accurately converted to data obtained
with blood by multiplying water results by 2 to 3 times depending
on the conditions of the experiment, as detailed in the work of
Vaslef and associates26 and confirmed by our laboratory.27 The test
circuit consisted of an acrylic test section with a 1-inch (25 mm)
inner diameter, 2 compliance bags on both ends of the test section,
a Biomedicus centrifugal pump, a reservoir container, a circulating
temperature bath, and a standard extracorporeal oxygenator used to
establish desired test section inlet oxygen and carbon dioxide
conditions. A 3/4-inch (19 mm) inner diameter test section was
also interchanged with the 1-inch (25 mm) piece to evaluate the
effects of vessel diameter on gas exchange and water side pressure
decreases across the device. A rotameter was used to measure
water flow, and a thermocouple thermometer was used to measure
water temperature immediately after the test section. All reported
in vitro gas exchange measurements were made at a water flow
*Also reported in previous publications as the intravenous membrane oxy-
genator. The catheter-based device, however, exchanges both oxygen and car-
bon dioxide. Simply describing it as a membrane oxygenator is not accurate.
The HC is intended for respiratory support in cases of acute respiratory failure.
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rate of 3 L/min and inlet gas tensions of 50 mm Hg for carbon
dioxide and 30 mm Hg for oxygen. Pure oxygen gas was pulled
through the fibers under vacuum conditions at a flow rate of 3
L/min, which corresponded to the minimum rate at which carbon
dioxide removal was not compromised but which provided a
minimal gas side pressure decrease so as to maintain a large
driving gradient for oxygen exchange.28 Balloon pulsation was
driven with a specially designed pneumatic drive system consist-
ing of positive pressure and a vacuum reservoir connected through
alternating solenoid valves to a safety chamber enclosing an ex-
ternal balloon. The inside of this balloon was connected by a tube
to the device balloon pathway so that pressurization of the external
balloon resulted in inflation of the device balloon and vice versa.
Gas exchange measurements for each device were measured over
a range of balloon pulsation rates spanning 0 beats/min to the
maximum rate at which the given balloon size could be fully
inflated and deflated, as determined with a plethysmograph. Car-
bon dioxide exchange was calculated from measurements of the
sweep gas mass flow rate and the percentage of carbon dioxide
exiting the fiber bundle (measured with a mass spectrometer),
whereas oxygen exchange was calculated from measurements of
the water flow and the difference in partial pressure of oxygen in
the water flow before and after device insertion, as measured with
a blood gas analyzer (radiometer).
Acute In Vivo Characterization
The in vivo performance of the HC with different balloon volumes
was studied in 7 calves weighing 93.9  9.9 kg. A detailed
description of the methods used for animal preparation, mainte-
nance, and monitoring for insertion and characterization of the HC
device can be found in a previous publication.14 In short, the calves
were anesthetized, intubated, and placed on a volume-controlled
ventilator. Before device insertion, a 7F Swan-Ganz thermodilu-
tion catheter (Edwards Lifesciences, Irvine, Calif) was inserted
through the left internal jugular vein for measurement of cardiac
output, central venous pressure, pulmonary artery pressure, and
blood gases after device insertion. Additionally, a pressure-moni-
toring catheter was inserted into the common iliac vein through the
left femoral vein for measurement of blood pressure and gas
tensions before device insertion, as well as for continuous delivery
of heparin. Finally, an 18-gauge arterial catheter was inserted into
the right carotid artery for measurement of arterial blood pressures
and gas tensions.
Blood gases, pressures, and cardiac outputs were measured
every half hour during the course of the experiment in addition to
special measurements taken immediately before and after device
insertion and after changes in balloon pulsation rate. Because these
devices did not yet have a heparin molecule attached to the
microporous hollow fiber membrane surface, animals were hepa-
rinized with an initial bolus (400 U/kg) immediately before device
insertion and through a continuous drip (0.5-1.0 mg  kg1  h1)
initiated thereafter. Activated clotting time was measured every
half hour, with a target level of greater than 450 seconds. Levels of
plasma-free hemoglobin were measured after surgical preparation
but before device insertion and throughout the experiment.
The HC device was preloaded into a removable Teflon sheath
that minimized the insertion size of the fiber bundle and the
friction with the vessel wall during insertion. Each device was then
inserted into the vena cava through the left internal jugular vein.
The device was positioned such that the distal manifold was in the
IVC approximately at the diaphragm, with the fiber bundle span-
ning the right atrium and the proximal manifold in the SVC. After
Figure 1. The amount of oxygen that a respiratory assist catheter positioned in the venous system would have to
add to an adult patient with a normal hematocrit level, cardiac output of 5 L/min, and venous PO2 of 39 mm Hg to
achieve an arterial PO2 of 60 mm Hg, as determined by the amount of residual lung still functional.
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each device was inserted and positioned, balloon pulsation was
immediately initiated at 120 beats/min, followed by initiation of
sweep gas flow (100% oxygen) at 3 L/min. Gas exchange charac-
terization began after an initial stabilization period, during which
the ventilator was used to adjust the venous carbon dioxide tension
to within 10% of 50 mm Hg. The gas exchange performance was
characterized for each device by measuring the carbon dioxide
exchange at randomly varied beat rates of 0, 30, 60, 120, 180, 240,
and 300 beats/min, with 2 sets of data at each beat rate. In 5 of the 7
calf experiments, the device was repositioned after characterization in
the right atrium location such that it was entirely within the IVC,
spanning the renal veins. Characterization was repeated in the IVC
location for comparison with the results in the right atrium position.
Minute ventilation was reduced in some animals to stress the
ability of the device to remove carbon dioxide under hypercapnic
conditions, with a concomitant venous PCO2 increase. The carbon
dioxide gas exchange rate was calculated by multiplying the sweep
gas flow rate by the carbon dioxide gas fraction exiting the device.
The carbon dioxide exchange rate depends on the venous blood
PCO2 in contact with the fiber bundle, which can differ among
experiments and animals, even with appropriate ventilatory adjust-
ments. For a more direct comparison between devices, we normal-
ized the carbon dioxide exchange rate to a venous PCO2 of 50 mm
Hg. This normalized carbon dioxide exchange rate was determined
by multiplying the carbon dioxide exchange by 50 mm Hg divided
by the measured Pco2.
Oxygen exchange was not used to characterize the device
performance because of the difficulty in obtaining accurate mea-
surements in vivo. Calculation of oxygen exchange on the blood
side would require the ability to accurately measure blood flow
past the portion of the device in the SVC and concurrently to the
portion in the IVC, and if these measurements could in fact be
made, they would not reflect the changes in flow rate caused by the
various venous pathways converging along the vena cava. On the
gas side, accurate measurement of oxygen exchange is limited by
the small difference in mass flow rate and oxygen fraction entering
and exiting the fiber bundle. The standard error of the oxygen
exchange calculation from gas flow measurements would be
greater than the difference in oxygen exchange rate between de-
vices.
After completion of the acute trials, the animal was deeply
anesthetized and killed with a bolus of potassium chloride, fol-
lowed by complete autopsies. All animal procedures were con-
ducted under supervision of a staff surgical veterinarian and were
in accordance with National Institutes of Health and University of
Pittsburgh guidelines for the care and use of experimental animals
in research.
Chronic In Vivo Characterization
For the chronic in vivo trials, HC devices with 13-mL balloons
were inserted into the IVC position and characterized according to
the same procedure used for the acute experiments. The IVC
position was chosen because once animals were awake and stand-
ing in their stalls, the IVC was the only anatomic location where
the devices remained straight in conıguration without concerns
over kinking. After characterization, the calf was revived and
transferred to a postoperative critical and long-term animal care
room. All catheters remained in the calf for long-term monitoring
of pressures, blood gases, hematocrit levels, blood chemistry, and
cardiac output. Heparin was continuously administered through the
femoral vein line so that activated clotting times remained between
400 and 500 seconds for the first day and between 200 and 300
seconds thereafter. Units of blood were administered as needed on
the basis of hematocrit levels. Balloon pulsation was maintained at
120 beats/min continuously with a Datascope intra-aortic balloon
console (because of its autofilling capability). Sweep gas flow rate
and fraction of carbon dioxide in the gas exiting the fibers were
continuously recorded in a computer for calculation of carbon
dioxide exchange. Gas exchange, hemodynamics, and hematologic
evaluation were carried out for a 4-day period. After completion,
the animal was anesthetized and killed in the same manner as for
the acute trials. Full autopsies were carried out immediately after
trial termination.
Results
In Vitro
The average in vitro oxygen and carbon dioxide exchange
results in water for devices having a 13-, 25-, and 40-mL
Figure 2. A schematic of the respiratory assist catheter (RAC). The
exit manifold is positioned outside the body, where the 3 ports
can be accessed for oxygen (100%) delivery, vacuum, and a
helium port connected to an external console that drives pulsa-
tion of the balloon up to 300 beats/min. The hollow fiber bundle
attached to the end of the gas delivery catheter is 30 to 40 cm long
and can very in surface area from 0.17 to 0.43 m2.
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balloon, respectively, are shown in Figures 3 and 4. The gas
exchange results are shown both as a function of the balloon
pulsation rate and the balloon-generated flow rate, which is
determined from twice the pulsation rate (blood is moved
both in inflation and deflation) multiplied by the balloon
volume. The maximum pulsation rate at which a given
balloon volume can be fully inflated and deflated is gov-
erned by the pressure and vacuum pump capacities of the
drive system, as well as by the helium flow pathway char-
acteristics leading to the balloon. When this maximum
pulsation rate is exceeded and the balloon is no longer able
to fully inflate or deflate, the gas exchange begins to plateau,
as shown in the bottom graphs of Figures 3 and 4. From the
bottom graphs, it can be seen that the larger the balloon, the
better the maximum achievable gas exchange. However, to
separate the limitations of the balloon drive system from
inherent differences in gas exchange between devices with
different balloon sizes, the gas exchange is also shown as a
function of the balloon-generated flow (ie, the amount of
fluid per minute pumped in and out of the fiber bundle by
the balloon). From these results (upper graphs of Figures 3
and 4), it was found that the larger balloon devices still
outperformed the smallest balloon device for a given bal-
loon-generated flow rate. The maximum achieved gas ex-
change rate in a 25-mm test section with water flowing at 3
L/min was 240 mLSTP  min1  m2 for carbon dioxide and
140 mLSTP  min1  m2 for oxygen, which occurred with
the largest balloon device at a balloon-generated flow of
approximately 24 L/min.
The gas exchange results in a 25-mm test section also
showed that a larger balloon device performed substantially
better than a smaller balloon device when the balloon was in
a static, nonpulsing, deflated mode. These results suggest
that the size of the bundle diameter, which is determined by
the balloon size, is the factor that leads to improved gas
exchange performance (Table 1). The 25-mL and 13-mL
devices were tested in a 19-mm test section at the same flow
rate to further evaluate this result (the 40-mL devices would
not easily fit in this size test section). Figure 5 shows the
carbon dioxide exchange results in the 19-mm section test
versus those in the 25-mm test section. For both devices, the
gas exchange was 25% higher (P  .05) in the smaller test
section, and the larger balloon device outperformed the
smaller device both at maximum pulsation rate and in the
Figure 3. Average carbon dioxide exchange in water with a
1-inch test section. Numbers are an average of 6 to 8 determina-
tions for each designated point. The diameter of the mock vena
cava test section was 1 inch (25 mm).
Figure 4. Average oxygen exchange in water with a 1-inch test
section. Numbers are an average of 6 to 8 determinations for each
designated point.
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static balloon-deflated mode. In the 19-mm test section, the
maximum carbon dioxide exchange of the 25-mL balloon
device was 255 mLSTP  min1  m2, whereas in a 25-mm
test section it was 205 mLSTP  min1  m2.
The improved exchange, however, was at the expense of
a pressure decrease across the device. Table 1 shows the
decrease in pressure measurements at 3 L/min water flow
for each device in the 2 test sections. In the 25-mm test
section the maximum pressure decrease for the largest bal-
loon device at maximum pulsation rate was 3.3 mm Hg.
However, in the 19-mm test section the average pressure
decrease across the length of the 25-mL balloon device was
29 mm Hg, and for the 13-mL balloon device, it was 4.5 mm
Hg at a pulsation rate of 300 beats/min.
Acute In Vivo
Seven acute in vivo calf tests were conducted in which 2
and, when possible, 3 devices, each having a different
balloon size, were tested in the right atrium and in the IVC
of each animal. Figure 6 is representative of the carbon
dioxide exchange results generated during each of the 7
acute tests. All devices tested generated greater gas ex-
change in the right atrium region compared with that in the
IVC region. In each test, as reflected in Figure 6, one device
clearly removed more carbon dioxide than the others. Figure
7 shows the carbon dioxide exchange results in the right
atrium position for each test, with the average performance
of all tests per balloon size shown on the far right. As shown
in Figure 7, the results were inconsistent in different calves
as to which balloon size device performed better. Correlat-
ing these findings with postmortem determinations of the
size of the vena cava and the right atrium is difficult because
of the rapid change in compliance of these structures after
death. Nevertheless, we interpret these findings as most
consistent with gas exchange, as determined by the relation-
ship of the device size to that of its containing chamber.
This interpretation is consistent with our in vitro experi-
ments measuring gas exchange of various size devices in
19- and 25-mm test sections (Figure 5).
Hemodynamically, and particularly for 40-mL balloon
devices, the cardiac output was significantly affected by
insertion of the device into the right atrium, as shown in
Table 2. Smaller devices had no statistically significant
effect on cardiac output. These findings are most consistent
with the important relationship that exists between the size
of the device, the vascular anatomy of the recipient, and
venous return.
The average carbon dioxide exchange for all devices of
a given balloon size in the right atrium position compared
with that seen in the IVC position is shown in Figure 8. For
each location, there was no statistical difference between
balloon sizes, but there was a significant difference in car-
bon dioxide exchange between locations (P  .05, right
atrium vs IVC). In the right atrium position the average
carbon dioxide exchange was approximately 305 mLSTP 
min1  m2, and in the IVC position it was approximately
265 mLSTP  min1  m2.
Chronic In Vivo
The carbon dioxide exchange rate of a 13-mL balloon
device in the IVC position was recorded during 2 chronic in
vivo trials lasting 4 days each. Although devices spanning
the right atrium show better gas exchange (Figure 6), the
IVC position was necessary to maintain the device in a
straight conıguration without concerns over kinking once
the calf awakened and stood up. These gas exchange values
were recorded with the animal awake and with the balloon
pulsing at 120 beats/min. For both trials, the carbon dioxide
exchange rate was found to be consistently within a range of
220 to 280 mLSTP  min1  m2, with little to no gas
exchange degradation over the 4-day period. These results
reflect gas exchange at a suboptimal beat rate necessitated
by the need to use a Datascope console because of its
autofilling capability.
TABLE 1. Comparison of average pressure decrease across devices of different balloon sizes and at different pulsation
rates. The effective outer diameter of the fiber bundles for each size balloon device is also shown. Tube diameters are
expressed in inches and millimeters
Balloon
volume
Inflated outer
diameter
3/4-inch Tube (19 mm) 1-inch Tube (25 mm)
BPM
Mean pressure decrease
(mm Hg) BPM
Mean pressure decrease
(mm Hg)
13 mL 15 mm 0 2.4% 4.6% 0 0.8% 8.4%
180 5.2% 1.3% 180 1.0% 0.0%
300 4.5% 2.2% 300 1.2% 4.0%
25 mL 17 mm 0 7.7% 0.3% 0 2.4% 2.9%
180 27.1% 5.5% 180 2.8% 2.8%
300 28.6% 7.0% 300 3.4% 0.6%
40 mL 19 mm — — 0 0.9% 1.1%
— — 180 3.1% 0.7%
— — 300 3.3% 0.9%
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For both chronic trials, the initial samples for plasma-
free hemoglobin were taken after the jugular vein had been
exposed for insertion but before the device had actually
been inserted. In the first trial the plasma-free hemoglobin
levels began at 6 mg/dL (before insertion) and increased to
12 mg/dL during the first 24 hours, then gradually decreased
over the course of the trial to a final level of 5 mg/dL. In the
second trial the level of plasma-free hemoglobin began at 9
mg/dL and from that point gradually declined over the
4-day trial to a final level of 4 mg/dL.
Changes in the carbon dioxide exchange rate during
permissive hypercapnea are shown in Table 3. An increase
in the carbon dioxide exchange was observed from a base-
line venous PCO2 of 49 mm Hg to an increased PCO2 of 67
mm Hg during implantation of the HC in a calf. The carbon
dioxide exchange rate is shown as the fractional increase
relative to that of the baseline PCO2. The device increased its
carbon dioxide exchange rate by 48% in response to the
permissive hypercapnea, an increase somewhat greater than
the percentage increase in PCO2 associated with the hyper-
capnea.
Autopsies of these animals were unremarkable, with no
distal emboli. A small amount of fibrin deposition at the
distal and proximal manifolds of the device was observed.
Discussion
Recent reports have indicated that acute respiratory failure
in the United States has an incidence of greater than 300,000
cases per year. In the adult population the mortality ranges
from 11% to 60%, depending on the age group studied.29
The need for improved care in this patient population has
formed the basis for a continuing interest in the develop-
ment of better ventilator strategies, new drug therapies, and
artificial lung devices, including improved approaches to
extracorporeal membrane oxygenation in the treatment of
acute lung failure and in the management of patients on
ventilators.
In this context our efforts have concentrated on the
development of a respiratory assist catheter that will allow
reductions in ventilator support by providing up to 50% of
the gas exchange requirements (125 mL/min oxygen and
carbon dioxide) in ventilator patients with reversible acute
respiratory failure. This level of respiratory support can be
calculated to have a beneficial effect in adult patients with
only 30% of their lung functional (Figure 1). Because the
device is not intended for total support, it depends on the
fact that damage to the lungs in patients with ARDS is not
uniform and that numerous areas of normal lung can be
demonstrated throughout severely diseased segments.30 The
ability to lower tidal volumes and to more gently ventilate
these normally compliant lung segments appears to have
survival value in the patient with ARDS and is instrumental
in the conceptual approach to eventually implementing a
respiratory assist catheter in a clinical setting.5
Figure 5. Comparison of carbon dioxide exchange of a 13-mL and
25-mL balloon device in a 1-inch (25 mm) test section versus a
3/4-inch (19 mm) test section.
Figure 6. Example of short-term in vivo test results from test 3.
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A key element of the respiratory assist catheter under
development is a central pulsating balloon that significantly
enhances gas exchange in the venous system. The goal of
the present experiments was to characterize the gas ex-
change and hemodynamic effects of the respiratory assist
catheter as a function of balloon size in large animals with
weights equivalent to those of human subjects. In the con-
trolled in vitro environment of the mock venous circulatory
system, the results clearly demonstrated that a device with a
larger balloon provided higher gas exchange rates, both for
carbon dioxide and oxygen (Figures 3-5). The larger bal-
loon devices not only could be driven to generate a larger
balloon flow but, for a given balloon-generated flow rate,
yielded a larger gas exchange rate. A larger balloon inher-
ently pulses with a greater stroke volume, which penetrates
more effectively across the fiber bundle than a smaller
balloon.
Device size as a function of the diameter of the mock
vena cava was also examined in the in vitro circulatory
system. Gas exchange for a device uniformly improved as
Figure 7. Summary of acute in vivo test results in 7 calves. Average carbon dioxide exchange for each balloon size
over all tests is shown to the right. There was no statistical difference in average exchange on the basis of balloon
size.
TABLE 2. Summary of cardiac output measurements made during acute invivo trials before and after device insertion, while
device was in the right atrium position
Cardiac output in the right atrium (L/min)
Test 1 Test 2 Test 3 Test 4 Test 5 Test 6 Test 7
Animal
size (kg) 110 92 103 79 90 92 91
Insertion Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post
40 mL 10.9 5.1 8.1 8.3 — — 8.7 7.0 — — — — 10.1 6.1
25 mL 13.2 12.3 9.2 10.2 13.5 12.6 9.3 9.3 7.6 6.7 8.8 7.2 — 9.8
13 mL — — — — 13.5 14.3 9.7 8.6 7.6 8.5 8.8 8.1 9.6 8.8
Testing was carried out in 7 calves.
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the diameter of the test section was reduced (Figure 5).
Similar findings have also been reported by von Segesser
and associates31 and reflect the increased longitudinal fluid
velocities in smaller vessels, which can more effectively
penetrate the fiber bundle. A point is reached, however, with
smaller diameter conduits at which the pressure decrease
across the device becomes excessive (Table 1), and any
extrapolation to an in vivo setting would not be hemody-
namically tolerated.
With in vitro testing, the fluid is mechanically circulated
at a fixed rate past the respiratory assist catheter, regardless
of pressure decreases engendered by resistance to flow.
These issues, however, become paramount when testing in
vivo, where, in contrast to in vitro results, the acute in vivo
results were much less consistent between balloon sizes.
These findings are best interpreted as reflecting the impor-
tant relationship that exists between the size of the device
and the central venous anatomy of the recipient. The largest
40-mL balloon devices in the position spanning the right
atrium resulted in a significant reduction in cardiac output in
3 of the 4 trials in which the larger device was tested. In no
case did a device with a 25-mL or 13-mL balloon cause
such a result in 90- to 100-kg calves. For each individual
test, one device would clearly outperform the other, as
typified by Figure 7. There was no difference, however, in
gas exchange performance when averaged over all trials
(Figure 7). Therefore, smaller balloon devices that can
generate comparable balloon flow (2 balloon size  beat
rate) at faster beat rates would appear to have significant
advantage in terms of safety, ease of insertion, and hemo-
dynamic stability of the recipient.
The in vivo carbon dioxide exchange levels were, on
average, 305 mL  min1  m2. Thus with an anticipated
device membrane surface area of 0.4 m2, for an average
adult male patient, a carbon dioxide exchange rate of 125
mL/min, or approximately 50% of basal carbon dioxide
production, is expected if the device performance scales
linearly with surface area. Devices with membrane surface
areas of 0.5 m2 were tested in human subjects in the early
1990s by Mortenson and colleagues24 without hemody-
namic concerns. Although oxygen exchange could not be
accurately measured in vivo, an estimation of in vivo oxy-
gen exchange can be projected from our in vitro results.
Vaslef and coworkers26 have demonstrated that the oxygen
exchange rate of membrane oxygenators tested in blood
consistently correlated with exchange rates in water by a
factor of 2 to 3. Our own studies comparing the performance
of the HC device in an in vitro circuit filled with water
versus with blood demonstrated a similar correlation fac-
tor.27 The in vitro water results for the 3 balloon sizes
demonstrated maximum exchange rates of 140 mL  min1
 m2, which, for a device of 0.4 m2, corresponds to an
oxygen exchange rate of 56 mL/min. Using the water-to-
blood correlation factor of 2 to 3, an in vivo oxygen ex-
change rate of 110 to 170 mm/min is predicted, which is
approximately 50% of basal metabolic oxygen consump-
tion.
Devices positioned so as to span the right atrium dem-
onstrated significantly better gas exchange when compared
with devices positioned entirely in the IVC (Figure 8).
Under these latter conditions, blood entering the right
atrium from the upper body would not be exposed to the gas
exchange fibers, creating a significant shunt fraction with
reduced overall gas exchange.
While awaiting longer animal-testing capabilities, de-
vices were chronically tested in vivo for 4 days with sus-
tained gas exchange in calves and normal functioning de-
vices at the time of animal death. Although the goal for the
respiratory assist catheter is 7 to 10 days of pulmonary
support, shorter intervals might be of benefit. The recent
Figure 8. Acute in vivo average maximum carbon dioxide ex-
change I the right atrium and IVC positions in 7 calves.
TABLE 3. Effect of permissive hypercapnea on carbon di-
oxide exchange during acute implantation in the calf
Venous PCO2
(mm Hg)
VCO2 normalized to VCO2 at
venous PCO2 of 49.1 mm Hg PCO2/49.1 mm Hg
49.1 (baseline) 1 1
54.3 1.13 1.11
60.2 1.33 1.23
63.3 1.44 1.29
66.9 1.48 1.36
VCO2, Carbon dioxide consumption.
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National Institutes of Health trial has provided evidence that
as early as 48 hours after the institution of a lung-protective
strategy, an improvement in the pulmonary status of pa-
tients with ARDS can be seen.5 Jayroe and associates32 have
confirmed these clinical findings in an ovine smoke inhala-
tion model of acute lung injury. Importantly, and as part of
this therapy with reductions in tidal volume and minute
ventilation, hypercapnea is inevitable. The ability of the
respiratory assist catheter to increase its carbon dioxide
output with permissive hypercapnea (Table 3) would predict
its ability to respond to tidal volume reduction in the therapy
of acute respiratory failure.
In summary and as part of a continuing evaluation of gas
exchange in the venous system,4,11-28 the present work sup-
ports the concept that a respiratory assist catheter can be
made both hemodynamically compatible and gas exchange
efficient while providing 50% of the basal gas exchange
requirements in human subjects. Whether this level of gas
exchange will prove beneficial in a patient setting will be
determined in clinical trials.
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Discussion
Dr Diedrich E. Birnbaum (Regensburg, Germany). I think it
is still a fascinating device. However, the clinical situation is quite
different from what we learned from the cows in gas exchange. In
the clinical setup, normally the condition of the patients is septic
and they are in chronic pulmonary failure. Therefore, to deliver
oxygen is one side in this situation, and acidosis is the other side.
Therefore, the gas exchange is only one part, which certainly can
be fulfilled by these devices. However, coagulation-anticoagula-
tion situations in these patients and results on acidotic situations of
these patients are very important, and I wonder how this will be
evaluated enough in experimental setups to go on to the clinical
situation.
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Dr Hattler. Acidosis in these patients with respiratory fail-
ure is largely respiratory, and the device will remove carbon
dioxide very nicely. We did not show the pH values in these
cows, but they were maintained at normal levels. The devices
are coated with a heparin molecule that actually reduces the
need for anticoagulation, although it does not eliminate it.
Activated clotting times run in the range of 150 to 180 seconds.
Therefore, you can use this device with minimal anticoagula-
tion in the cow. Whether this will be true in human subjects, we
do not know yet.
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